Literature DB >> 27913571

SNORD126 promotes HCC and CRC cell growth by activating the PI3K-AKT pathway through FGFR2.

Xianlong Fang1, Dongmei Yang2, Hongping Luo3, Shuai Wu1, Wenjie Dong2, Jing Xiao1, Sujing Yuan1, Aimin Ni1, Kang-Jian Zhang1, Xin-Yuan Liu1,2, Liang Chu1,3.   

Abstract

Small nucleolar RNA (snoRNA) dysfunctions have been associated with cancer development. SNORD126 is an orphan C/D box snoRNA that is encoded within introns 5-6 of its host gene, cyclin B1-interacting protein 1 (CCNB1IP1). The cancer-associated molecular mechanisms triggered by SNORD126 are not fully understood. Here, we demonstrate that SNORD126 is highly expressed in hepatocellular carcinoma (HCC) and colorectal cancer (CRC) patient samples. SNORD126 increased Huh-7 and SW480 cell growth and tumorigenicity in nude mice. Knockdown of SNORD126 inhibited HepG2 and LS174T cell growth. We verified that SNORD126 was not processed into small RNAs with miRNA activity. Moreover, SNORD126 did not show a significant expression correlation with CCNB1IP1 in HCC samples or regulate CCNB1IP1 expression. Our gene expression profile analysis indicated that SNORD126-upregulated genes frequently mapped to the PI3K-AKT pathway. SNORD126 overexpression increased the levels of phosphorylated AKT, GSK-3β, and p70S6K and elevated fibroblast growth factor receptor 2 (FGFR2) expression. siRNA-mediated knockdown or AZD4547-mediated inactivation of FGFR2 in SNORD126-overexpressing Huh-7 cells inhibited AKT phosphorylation and suppressed cell growth. These findings indicate an oncogenic role for SNORD126 in cancer and suggest its potential as a therapeutic target.
© The Author (2016). Published by Oxford University Press on behalf of Journal of Molecular Cell Biology, IBCB, SIBS, CAS. All rights reserved.

Entities:  

Keywords:  CRC; FGFR2; HCC; PI3K–AKT; small nucleolar RNA

Mesh:

Substances:

Year:  2017        PMID: 27913571     DOI: 10.1093/jmcb/mjw048

Source DB:  PubMed          Journal:  J Mol Cell Biol        ISSN: 1759-4685            Impact factor:   6.216


  29 in total

Review 1.  Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.

Authors:  Chun-Ming Wong; Felice Ho-Ching Tsang; Irene Oi-Lin Ng
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-01-10       Impact factor: 46.802

Review 2.  Small non-coding RNAs in human cancer: function, clinical utility, and characterization.

Authors:  Zhao Zhang; Jian Zhang; Lixia Diao; Leng Han
Journal:  Oncogene       Date:  2021-01-15       Impact factor: 9.867

Review 3.  C/D-box snoRNAs form methylating and non-methylating ribonucleoprotein complexes: Old dogs show new tricks.

Authors:  Marina Falaleeva; Justin R Welden; Marilyn J Duncan; Stefan Stamm
Journal:  Bioessays       Date:  2017-05-15       Impact factor: 4.345

4.  Noncoding RNAs in inflammation and colorectal cancer.

Authors:  Shengyun Ma; Tianyun Long; Wendy Jia Men Huang
Journal:  RNA Biol       Date:  2019-12-26       Impact factor: 4.652

5.  Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies.

Authors:  Madhav Madurantakam Royam; Chellan Kumarasamy; Siddhartha Baxi; Ajay Gupta; Nachimuthu Ramesh; Gothandam Kodiveri Muthukaliannan; Rama Jayaraj
Journal:  Mol Diagn Ther       Date:  2019-02       Impact factor: 4.074

6.  The snoGloBe interaction predictor reveals a broad spectrum of C/D snoRNA RNA targets.

Authors:  Gabrielle Deschamps-Francoeur; Sonia Couture; Sherif Abou-Elela; Michelle S Scott
Journal:  Nucleic Acids Res       Date:  2022-06-24       Impact factor: 19.160

7.  Involvement of the oncogenic small nucleolar RNA SNORA24 in regulation of p53 stability in colorectal cancer.

Authors:  Liping Shen; Chuxian Lin; Wenqing Lu; Junyan He; Qi Wang; Yujv Huang; Xiaofei Zheng; Zhidong Wang
Journal:  Cell Biol Toxicol       Date:  2022-09-10       Impact factor: 6.819

Review 8.  Targeting snoRNAs as an emerging method of therapeutic development for cancer.

Authors:  Di Zhang; Juan Zhou; Jie Gao; Ri-Ying Wu; Ying-Long Huang; Qin-Wen Jin; Jian-Si Chen; Wei-Zhong Tang; Lin-Hai Yan
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

9.  LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.

Authors:  Ruyue Xu; Yinci Zhang; Amin Li; Yongfang Ma; Wenpeng Cai; Li Song; Yinghai Xie; Shuping Zhou; Weiya Cao; Xiaolong Tang
Journal:  Mol Med Rep       Date:  2021-05-13       Impact factor: 2.952

10.  CD105 expression is associated with invasive capacity in ovarian cancer and promotes invasiveness by inhibiting NDRG1 and regulating the epithelial-mesenchymal transition.

Authors:  Jin Zhang; Xiubo Sang; Rui Zhang; Jingjing Chi; Wenpei Bai
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.